Sign in
Taking peoplePhase 2

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Burkina Faso, Côte d’Ivoire, Gabon, Ghana, Kenya, and Uganda12 sites in 6 countriesChoose a country to see its sites
Trial code
Status
Recruiting
Phase
Phase 2
People taking part
327 people, planned
Started
23 Jan 2024
Planned end
23 Jun 2026
Type of study
Interventional, 10 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • INE963
  • KAE609 (Cipargamin)
  • SoC (Coartem)
  • KLU156
Record updated
30 July 2025

Who can take part

Age
2 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Male and female patients ≥18 years of age for Part A, ≥12 years of age for Part B and 2 to <12 years of age for Part C at screening
  • Patients must have acute uncomplicated P. falciparum malaria mono infection at screening confirmed by a parasite count between 5,000 to 150,000 asexual parasite count/μl of blood for P. falciparum for Part A and between 1,000 to 150,000 asexual parasite count/μl of blood for Parts B and C
  • Patients in Part A must weigh between 40 kg and 90 kg. Patients in Part B must weigh between 35 kg and 90 kg at screening. Patients in Part C must weigh at least 10 kg at screening
  • Axillary temperature ≥ 37.5ºC or oral/tympanic/rectal temperature ≥ 38.0ºC; or history of fever during the previous 24 hours

Who cannot take part

  • Patients with signs and symptoms of severe/complicated malaria at screening or mixed Plasmodium infection (i.e., infection with more than one malaria species) at screening
  • Any known/suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection at screening
  • Moderate to severe anemia, chronic hemoglobinopathy (Hemoglobin level < 8 g/dL), or known chronic underlying disease such as sickle cell disease at screening
  • Known clinically significant liver disease (e.g., chronic hepatitis, liver cirrhosis (compensated or decompensated), history of hepatitis B or C, hepatitis A or B vaccination in the last 3 months, known gallbladder or bile duct disease, acute or chronic pancreatitis. Clinical or laboratory evidence of any of the following at screening:; AST/ALT > 3 x the upper limit of normal range (ULN), regardless of the level of total bilirubin; AST/ALT > 1.5 and ≤ 2 x ULN and total bilirubin is > ULN; Total bilirubin > 2 x ULN, regardless of the level of AST/ALT
  • History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study such as:; Concomitant clinically significant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker; History of familial long QT syndrome or known family history of Torsades de Pointe; Resting heart rate (physical exam or 12 lead ECG) < 50 bpm; Other protocol-defined inclusion/exclusion criteria may apply
  • Pregnant or nursing (lactating) women, women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using methods of effective contraception, and sexually active patients not willing to practice effective contraception

The main criteria, as questions

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 2 and 100 years old?

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Platform study to evaluate the efficacy and safety of anti-malarial agents in patients with uncomplicated Plasmodium falciparum malaria

The 10 groups in the trial

  • Cohort A1: Dose Level 1 INE963Treatment being tested

    Treatment: INE963

  • Cohort A1: Dose Level 2 INE963Treatment being tested

    Treatment: INE963

  • Cohort A1: Dose Level 3 INE963Treatment being tested

    Treatment: INE963

  • Cohort B1: Cipargamin + INE963Treatment being tested

    Treatment: KAE609 (Cipargamin)

  • Cohort B1: SoC (Coartem)Existing treatment, for comparison

    Treatment: SoC (Coartem)

  • Cohort B2: Cipargamin + KLU156Treatment being tested

    Treatment: KAE609 (Cipargamin) and KLU156

  • Cohort B2: SoC (Coartem)Existing treatment, for comparison

    Treatment: SoC (Coartem)

  • Cohort C2: Cipargamin + KLU156Treatment being tested

    Treatment: KAE609 (Cipargamin) and KLU156

  • Cohort C2: SoC (Coartem)Existing treatment, for comparison

    Treatment: SoC (Coartem)

  • Cohort A1: Dose Level 4 INE963Treatment being tested

    Treatment: INE963

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multi-part, Multi-center PLATform Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Anti-malarial Agents Administered as Monotherapy and/or Combination Therapy IN Patients With Uncomplicated Plasmodium Falciparum Malaria
Criteria questions
Built from NCT05750628, who can take part
Record updated
30 July 2025